Results 81 to 90 of about 63,057 (294)

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

The N-terminal activation function AF-1 domain of ERα interacts directly with the C-terminal AF-2-holding ligand-binding domain to recruit the coactivator proteins.

PLoS ONE
Cryoelectron microscopy (cryo-EM) clarified the quaternary structure of the DNA complex of coactivator-bound estrogen receptor alpha (ERα), revealing the adjacency of the N-terminal domain (NTD) and C-terminal ligand-binding domain (LBD). ERα-NTD and LBD
Xiaohui Liu, Yutaka Matsuyama, Makiko Sugiyama, Keitaro Suyama, Takeru Nose, Miki Shimohigashi, Yasuyuki Shimohigashi   +6 more
doaj   +1 more source

Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2–ERα–GREB1 Transcriptional Axis

Cancer Research, 2017
Resistance to cancer treatment can be driven by epigenetic reprogramming of specific transcriptomes in favor of the refractory phenotypes. Here we discover that tamoxifen resistance in breast cancer is driven by a regulatory axis consisting of a master ...
Yan-Ming Wu, Zhao Zhang, Mauro E. Cenciarini, Cecilia J. Proietti, M. Amasino, Tao Hong, Mei Yang, Yiji Liao, Huai-Chin Chiang, V. Kaklamani, R. Jeselsohn, R. Vadlamudi, T. Huang, Rong Li, C. de Angelis, Xiaoyong Fu, P. Elizalde, R. Schiff, Myles A. Brown, Ke-Xin Xu   +19 more
semanticscholar   +1 more source

Abstract PD05-06: Is ERα a Tamoxifen Predictive Factor in ERα Negative Breast Cancer in Premenopausal Women?

, 2010
Background: The majority of breast cancers are hormone receptor positive, defined as estrogen receptor (ERα) and/or progesterone receptor (PR) positive. Adjuvant tamoxifen decreases the risk of recurrence and improves survival in hormone positive breast ...
A-C Källström, PE Jönsson, B Nordenskjöld, G Landberg, M Fernö, O. Stål   +5 more
core   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Increased Expression of Estrogen Receptor α-36 by Breast Cancer Oncogene IKKε Promotes Growth of ER-Negative Breast Cancer Cells

Cellular Physiology and Biochemistry, 2013
Background/Aims: The expression of estrogen receptor-α (ERα) is one of the most important diagnostic and prognostic factors of breast cancer. Recently, ERα-36 has been identified as a novel variant of ER-α.
Qihong Li, Haiyan Sun, Jingcai Zou, Cheng Ge, Kaitao Yu, Yuan Cao, Quan Hong   +6 more
doaj   +1 more source

Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer

Clinical Cancer Research, 2017
Purpose: FGFR1 amplification occurs in approximately 15% of estrogen receptor–positive (ER+) human breast cancers. We investigated mechanisms by which FGFR1 amplification confers antiestrogen resistance to ER+ breast cancer.
L. Formisano, K. Stauffer, C. Young, Neil E. Bhola, A. Guerrero-Zotano, V. Jansen, Mónica M. Estrada, K. Hutchinson, J. Giltnane, L. Schwarz, Yao Lu, J. Balko, O. Deas, S. Cairo, J. Judde, I. Mayer, M. Sanders, T. Dugger, R. Bianco, T. Stricker, C. Arteaga   +20 more
semanticscholar   +1 more source

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

Molecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park, Kyongman An, Gyeonghwa Kim, Soo‐Nyun Choi, Hong‐Ki Lee, Keun Hur, Kyu‐Shik Jeong   +6 more
wiley   +1 more source

Loss of ERα induces amoeboid-like migration of breast cancer cells by downregulating vinculin

Nature Communications, 2017
Oestrogen receptor alpha (ERα) is a well-known target of endocrine therapy for ERα-positive breast cancer. ERα-negative cells, which are enriched during endocrine therapy, are associated with metastatic relapse.
Yuan Gao, Zhaowei Wang, Qiang Hao, Wei-Na Li, Yujin Xu, Juliang Zhang, Wang-Qian Zhang, Shuning Wang, Shuo Liu, Meng-meng Li, Xiaochang Xue, W. Zhang, Cun Zhang, Ying-Qi Zhang   +13 more
semanticscholar   +1 more source

ERα localization to early endosomes.

, 2014
(A) MCF-7 cells were co-stained with anti-ERα Sp-1 and EEA1 N-19 antibodies both in the presence and in the absence of E2 (10 nM–15 min). pc DNA flag ERα (Nessi)-transfected HeLa cells were co-stained with anti-ERα HC-20 and EEA1 H-300 antibodies both in
Valeria Pesiri (552188), Maria Marino (525018), Filippo Acconcia (208478), Pierangela Totta (231516)   +3 more
core   +1 more source